<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03289338</url>
  </required_header>
  <id_info>
    <org_study_id>ZoleMethCNO</org_study_id>
    <nct_id>NCT03289338</nct_id>
  </id_info>
  <brief_title>Zoledronic Acid or Methylprednisolone for Active Charcot's Neuroarthropathy of Foot in Patients With Diabetes Mellitus</brief_title>
  <official_title>Zoledronic Acid or Methylprednisolone in the Management of Active Charcot's Neuroarthropathy of Foot in Patients With Diabetes Mellitus: A Randomized, Double-blind, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Charcot neuropathic osteoarthropathy (CNO) is a progressively destructive process resulting&#xD;
      from significant peripheral neuropathy of almost any aetiology. Diabetes mellitus has emerged&#xD;
      as the commonest cause of CNO.&#xD;
&#xD;
      The Charcot foot in diabetes poses many clinical challenges in its diagnosis and management.&#xD;
      The lacuna primarily lies in delineation of its etio-pathogenesis and consequently in&#xD;
      targeted treatment modalities. Although traditional approaches focus on neurotraumatic and&#xD;
      neurovascular theories, these fail to explain all the features of CNO, hence, other&#xD;
      hypotheses have been put forward.The current belief is that once the disease is triggered in&#xD;
      a susceptible individual, it is mediated through a process of uncontrolled inflammation&#xD;
      which, in turn, leads to osteolysis, fractures and joint destruction. Of these processes, the&#xD;
      involvement of the receptor activator of nuclear factor- кB (RANK) ligand&#xD;
      /RANK/osteoprotegerin (OPG) system in the process of acute CNO is particularly appealing and&#xD;
      suggests new pharmacological approaches.&#xD;
&#xD;
      Standard modalities of treatment include offloading and casting. Although various trials have&#xD;
      analysed the impact of medical agents including bisphosphonates, teriparatide and bone&#xD;
      stimulation techniques, the results have been either inconclusive or not translated into&#xD;
      clinical practice. Hence, there is no efficacious treatment of active CNO apart from the&#xD;
      traditional offloading. In view of recent advances in understanding of the disease process,&#xD;
      the target of intervention should, logically, be interruption of the inflammatory cascade and&#xD;
      subsequent osteoclast resorption. Zoledronic acid is the most potent bisphosphonate that has&#xD;
      been studied in clinical trials to date and has the distinctive profile of strong inhibitory&#xD;
      activity on the enzyme farnesyl pyrophosphate synthase, essential for osteoclast function.&#xD;
      Methylprednisolone conceivably has a potential benefit by offsetting the RANKL/OPG system&#xD;
      involved. There have been conflicting reports with bisphophosphonates in active CNO and&#xD;
      Zoledronic acid has been infrequently used despite being the most potent. Glucocorticoids&#xD;
      including methylprednisolone have also not been systematically tried in this condition.&#xD;
&#xD;
      We hypothesise that targeting the inflammatory cascade with Methylprednisolone and osteoclast&#xD;
      mediated damage by Zoledronic acid will address the basic etiopathogenesis of active CNO and&#xD;
      may result in earlier resolution of the disease activity. The above mentioned hypothesis is&#xD;
      hence, planned to be tested in a randomised, double-blind, placebo-controlled study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Charcot's neuroarthropathy has been identified since 1883, yet we have much to learn about&#xD;
      the pathophysiology and evidence based treatment options. Active CNO is characterised by&#xD;
      repetitive trauma leading to inflammation in an insensate foot. This includes polypeptide&#xD;
      receptor activator of nuclear factor-kB ligand (RANKL) which triggers the synthesis of the&#xD;
      nuclear transcription factor nuclear factor-kb (NF-kb), and this in turn stimulates the&#xD;
      maturation of osteoclasts from osteoclast precursor cells. At the same time, NF-kb stimulates&#xD;
      the production of the glycopeptide osteoprotegerin (OPG) from osteoblasts. This &quot;decoy&#xD;
      receptor&quot; acts as an effective antagonist of RANKL . It has been suggested that this results&#xD;
      in continual production of proinflammatory cytokines, RANKL, NF-kb, and osteoclasts, which in&#xD;
      turn leads to continuing local osteolysis .This has adequately demonstrated by an increase in&#xD;
      proinflammatory phenotypes of monocytes in those with active Charcot foot when compared with&#xD;
      diabetic control subjects. Also osteoclasts generated in vitro in the presence of macrophage&#xD;
      colony-stimulating factor and RANKL from patients with active CN have been shown to be more&#xD;
      aggressive and exhibit an increase in their resorptive activity compared with control&#xD;
      subjects. Motor neuropathy contributes to altered structure of the foot with resultant&#xD;
      abnormal loading. Finally, it is possible that peptides like calcitonin gene-related peptide&#xD;
      (CGRP) , which normally antagonizes the synthesis of RANKL, reduced due to neuropathy&#xD;
      increase the RANKL expression. Diabetes may predispose to occurrence of CNO through a number&#xD;
      of mechanisms. Apart from the presence of neuropathy and possible osteopenia, these include&#xD;
      the effects of advanced glycation end products, reactive oxygen species, and oxidized lipids,&#xD;
      which may all enhance the expression of RANKL in diabetes.&#xD;
&#xD;
      The average delay in the diagnosis of acute Charcot has been reported to be around 29 weeks.&#xD;
      Common misdiagnoses include cellulitis, erysipelas, deep vein thrombosis (DVT), venous&#xD;
      insufficiency, gout, pseudogout, acute inflammatory arthritis, fracture, sprain, tumor,&#xD;
      septic arthritis, osteomyelitis, Sudeck's atrophy, and rheumatoid arthritis. Delay in prompt&#xD;
      diagnosis and initiation of treatment results in progression of the pathology resulting in&#xD;
      rigid osseous deformity of the foot increasing the risk of callus formation, ulceration,&#xD;
      infection, and lower extremity amputation by 15- to 40-fold .With the propensity for&#xD;
      misdiagnosis and high potential for progression to a rigid foot deformity, early recognition&#xD;
      and prompt initiation of treatment is paramount.&#xD;
&#xD;
      Radiographs are the primary initial imaging method for evaluation of the foot in suspected&#xD;
      CNO. However, they may initially be normal or show subtle fractures and dislocations.&#xD;
      Magnetic resonance imaging (MRI) has a higher sensitivity that allows detection of subtle&#xD;
      changes in the early stages of active CNO when X-rays could still be normal. MRI primarily&#xD;
      images protons in fat and water and can depict anatomy and pathology in both soft tissue and&#xD;
      bone in great detail because of its unique capability of differentiating tissues with high&#xD;
      detail.&#xD;
&#xD;
      Treatment of CNO is aimed at offloading the foot, treating bone disease, and preventing&#xD;
      further foot fractures. Because of the various etiologies of increased local bone resorption&#xD;
      and/or secondary osteoporosis in patients with CNO and limited randomized placebo-controlled&#xD;
      trials in this area, treatment guidelines are largely based on professional opinion rather&#xD;
      than the highest level of clinical evidence. Hence, there remains a dearth of evidence based&#xD;
      medical management for Charcot neuroarthropathy. Offloading at the acute active stage of the&#xD;
      Charcot foot is the most important management strategy and could arrest the progression to&#xD;
      deformity. Ideally, the foot should be immobilized in an irremovable total contact cast&#xD;
      (TCC), which is initially replaced at 3 days, then checked each week. Edema reduction is&#xD;
      often remarkable in the first few weeks of treatment. The cast should be changed frequently&#xD;
      to avoid &quot;pistoning&quot; as the edema subsides.&#xD;
&#xD;
      However, It is important to take into consideration that TCC may actually have unfavorable&#xD;
      consequences including unnatural stress patterns, increased instability, loss of muscle tone,&#xD;
      proprioception and boe density.Also, they are not designed to affect the underlying&#xD;
      physiological mechanisms that cause bone destruction.In this context, treatment by&#xD;
      antiresorptive drugs emerges as an attractive option. Bone turnover in patients with active&#xD;
      CNO is excessive, hence bisphosphonates, by inhibiting osteoclast mediated resorption, have&#xD;
      an important role to play. However, there is little evidence to support their use at&#xD;
      present.Both oral and intravenous bisphosphonates have been studied in the treatment of CNO&#xD;
      in small randomized, double-blind, controlled trials or in retrospective controlled studies.&#xD;
      Whatever the precise pathophysiological mechanism of CNO, bone resorption and osteoclastic&#xD;
      hyperactivity is a major feature of the early acute stage of this condition and makes the use&#xD;
      of bone-resorption-inhibiting agents such as bisphosphonates(BPs) a logical therapeutic&#xD;
      approach. Theoretically, pharmacological treatment of CNO by BPs, which inhibit osteoclastic&#xD;
      resorption and may have direct anti-inflammatory properties, might slow or even stop the bony&#xD;
      destruction through its ability to cause macrophage apoptosis.&#xD;
&#xD;
      Selby et al first reported the use of a BP in the treatment of CNO. They administered 30 mg&#xD;
      pamidronate i.v.,followed by five infusions of pamidronate 60 mg every 2 weeks for 12 weeks&#xD;
      in six patients with diabetes and acute CNO. The treatment was associated with improvement in&#xD;
      local pain and a significant reduction in the activity of the CNO as measured by the decrease&#xD;
      in the temperature of the affected foot, from 3.4±0.7°C (mean±SE) to 1.0±0.5°C (p 0.05).&#xD;
      There was also a significant reduction in bone turnover as judged by alkaline phosphatase&#xD;
      (ALP) level, which fell by 25±3% compared with initial values (p&lt;0.001). Stansberry et al in&#xD;
      1999 reported a decrease in peak cutaneous blood flow in response to the infusion of 90 mg&#xD;
      pamidronate i.v. over 24 h in 20 patients with diabetes and CNO, suggesting a&#xD;
      anti-inflammatory action of pamidronate. In 1999, Young reported anecdotally two cases of&#xD;
      diabetic acute CNO treated with i.v. infusions of pamidronate associated with immobilisation.&#xD;
      After 3 months, the clinical outcome was judged favourable with a reduction in clinical signs&#xD;
      and an absence of deformity. Pakarinen et al. in 2002 retrospectively analysed clinical&#xD;
      records and X-rays of 36 feet with CNO from 1994 to 2000. Eighteen patients received BPP&#xD;
      treatment (pamidronate 30-60 mg i.v. once a week for 6 weeks) and no complications were&#xD;
      registered. There was no statistically significant difference in casting time between&#xD;
      patients who received (11 weeks) and patients who did not receive (13 weeks) pamidronate. In&#xD;
      this series, pamidronate infusions were used for selected individuals without any striking&#xD;
      benefits or disadvantages. Clinically, treatment with BP was associated with a more rapid&#xD;
      decrease in skin temperature, but this effect was not sustained. Effect on the pain differed&#xD;
      among studies, with one showing improvement but another showing none.Pakarinen et al tried&#xD;
      Zoledronic acid and reported that it did not reduce the duration of immobilization. Rather&#xD;
      there was an increase in total time for casting in subjects treated with Zoledronic&#xD;
      acid.Similar observations about longer time of immobilization with the use of BPs was&#xD;
      reported in the the recent multicentric observational audit of acute diabetic CNO in the UK.&#xD;
&#xD;
      Randomised trials looking into possible use of glucocorticoids in management of active CNO&#xD;
      have not been undertaken, possibly because of only recent understanding of the role of acute&#xD;
      inflammation triggering the osteolysis that characterizes CNO. Intravenous&#xD;
      supra-pharmacological doses of corticosteroids have been used in various inflammatory and&#xD;
      autoimmune conditions because they are cumulatively less toxic than sustained steroid&#xD;
      treatment at lower quantitative dosage. Their action is supposed to be mediated through&#xD;
      non-genomic actions within the cell. When corticosteroids are administered as pulses, an&#xD;
      immediate profound anti-inflammatory effect is achieved, inflammatory damage is minimized ,&#xD;
      toxicity is low and there is no prolonged suppressive effect on the hypothalamic-pituitary&#xD;
      axis. But there are no randomized trials looking into the efficacy and potential benefit of&#xD;
      methylprednisolone in CNO as of date.&#xD;
&#xD;
      Hence this trial was designed to compare the therapeutic efficacy and profiles of two well&#xD;
      known agents Zoledronic acid (antiresorptive) and Methylprednisolone (anti-inflammatory) in&#xD;
      patients of diabetes mellitus with active CNO of foot.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time for resolution of active Charcot foot</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time for reduction in levels of inflammatory cytokines (&gt;= 50%)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for radiologic resolution/reduction on MRI</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Charcot Arthropathy</condition>
  <condition>Diabetes Complications</condition>
  <arm_group>
    <arm_group_label>Zoledronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bisphosphonate Zoledronic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucocorticoid Methylprednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebos</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid</intervention_name>
    <description>Zoledronic acid 5mg intravenous once a month for 3 months</description>
    <arm_group_label>Zoledronic acid</arm_group_label>
    <other_name>Zoledronate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone 1gm intravenous once a month for 3 months</description>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <other_name>MPS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Normal saline intravenous once a month for 3 months</description>
    <arm_group_label>Placebos</arm_group_label>
    <other_name>NS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with Diabetes mellitus with active Charcot neuroarthropathy of foot as per&#xD;
        following criteria:&#xD;
&#xD;
        Clinical criteria&#xD;
&#xD;
          1. Warm, swollen and erythematous foot&#xD;
&#xD;
          2. Skin temperature exceeding 2°C at the clinically suspected site of the affected foot&#xD;
             compared with a similar site on the contralateral foot (infrared thermometer)&#xD;
&#xD;
        Radiologic criteria MRI suggestive of acute CNO-&#xD;
&#xD;
          1. Osteopenia&#xD;
&#xD;
          2. Joint subluxation&#xD;
&#xD;
          3. Normal or low normal marrow signal on T1 MRI&#xD;
&#xD;
          4. Bone marrow edema on T2W MRI&#xD;
&#xD;
          5. Microfractures&#xD;
&#xD;
          6. Cortical disruption&#xD;
&#xD;
          7. Several joints or bones&#xD;
&#xD;
          8. Preserved periarticular subcutaneous fat&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Infected foot ulcer&#xD;
&#xD;
          2. Osteoporosis at lumbar spine or hip&#xD;
&#xD;
          3. Gouty arthritis&#xD;
&#xD;
          4. Active peptic ulcer disease&#xD;
&#xD;
          5. Any prior long term steroid intake for asthma, SLE, RA or IBD in the last 3 months&#xD;
&#xD;
          6. eGFR 45 ml/min or less&#xD;
&#xD;
          7. Active dental caries&#xD;
&#xD;
          8. Active upper gastrointestinal disease&#xD;
&#xD;
          9. Uncorrected Vitamin D deficiency&#xD;
&#xD;
         10. Peripheral vascular disease (ABI 0.9 or less)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil Bhansali, DM</last_name>
    <role>Study Director</role>
    <affiliation>Postgraduate Institute of Medical Education and Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Endocrinology, PGIMER</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 18, 2017</study_first_submitted>
  <study_first_submitted_qc>September 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2017</study_first_posted>
  <last_update_submitted>July 13, 2019</last_update_submitted>
  <last_update_submitted_qc>July 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Ashu Rastogi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Zoledronic acid</keyword>
  <keyword>Methylprednisolone</keyword>
  <keyword>Active Charcot's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthropathy, Neurogenic</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03289338
org study id: ZoleMethCNO
nct id: NCT03289338
lead sponsor: 
has dmc: Yes
Charcot neuropathic osteoarthropathy (CNO) is a progressively destructive process resulting
      from significant peripheral neuropathy of almost any aetiology. Diabetes mellitus has emerged
      as the commonest cause of CNO.

      The Charcot foot in diabetes poses many clinical challenges in its diagnosis and management.
      The lacuna primarily lies in delineation of its etio-pathogenesis and consequently in
      targeted treatment modalities. Although traditional approaches focus on neurotraumatic and
      neurovascular theories, these fail to explain all the features of CNO, hence, other
      hypotheses have been put forward.The current belief is that once the disease is triggered in
      a susceptible individual, it is mediated through a process of uncontrolled inflammation
      which, in turn, leads to osteolysis, fractures and joint destruction. Of these processes, the
      involvement of the receptor activator of nuclear factor- кB (RANK) ligand
      /RANK/osteoprotegerin (OPG) system in the process of acute CNO is particularly appealing and
      suggests new pharmacological approaches.

      Standard modalities of treatment include offloading and casting. Although various trials have
      analysed the impact of medical agents including bisphosphonates, teriparatide and bone
      stimulation techniques, the results have been either inconclusive or not translated into
      clinical practice. Hence, there is no efficacious treatment of active CNO apart from the
      traditional offloading. In view of recent advances in understanding of the disease process,
      the target of intervention should, logically, be interruption of the inflammatory cascade and
      subsequent osteoclast resorption. Zoledronic acid is the most potent bisphosphonate that has
      been studied in clinical trials to date and has the distinctive profile of strong inhibitory
      activity on the enzyme farnesyl pyrophosphate synthase, essential for osteoclast function.
      Methylprednisolone conceivably has a potential benefit by offsetting the RANKL/OPG system
      involved. There have been conflicting reports with bisphophosphonates in active CNO and
      Zoledronic acid has been infrequently used despite being the most potent. Glucocorticoids
      including methylprednisolone have also not been systematically tried in this condition.

      We hypothesise that targeting the inflammatory cascade with Methylprednisolone and osteoclast
      mediated damage by Zoledronic acid will address the basic etiopathogenesis of active CNO and
      may result in earlier resolution of the disease activity. The above mentioned hypothesis is
      hence, planned to be tested in a randomised, double-blind, placebo-controlled study.
Charcot's neuroarthropathy has been identified since 1883, yet we have much to learn about
      the pathophysiology and evidence based treatment options. Active CNO is characterised by
      repetitive trauma leading to inflammation in an insensate foot. This includes polypeptide
      receptor activator of nuclear factor-kB ligand (RANKL) which triggers the synthesis of the
      nuclear transcription factor nuclear factor-kb (NF-kb), and this in turn stimulates the
      maturation of osteoclasts from osteoclast precursor cells. At the same time, NF-kb stimulates
      the production of the glycopeptide osteoprotegerin (OPG) from osteoblasts. This "decoy
      receptor" acts as an effective antagonist of RANKL . It has been suggested that this results
      in continual production of proinflammatory cytokines, RANKL, NF-kb, and osteoclasts, which in
      turn leads to continuing local osteolysis .This has adequately demonstrated by an increase in
      proinflammatory phenotypes of monocytes in those with active Charcot foot when compared with
      diabetic control subjects. Also osteoclasts generated in vitro in the presence of macrophage
      colony-stimulating factor and RANKL from patients with active CN have been shown to be more
      aggressive and exhibit an increase in their resorptive activity compared with control
      subjects. Motor neuropathy contributes to altered structure of the foot with resultant
      abnormal loading. Finally, it is possible that peptides like calcitonin gene-related peptide
      (CGRP) , which normally antagonizes the synthesis of RANKL, reduced due to neuropathy
      increase the RANKL expression. Diabetes may predispose to occurrence of CNO through a number
      of mechanisms. Apart from the presence of neuropathy and possible osteopenia, these include
      the effects of advanced glycation end products, reactive oxygen species, and oxidized lipids,
      which may all enhance the expression of RANKL in diabetes.

      The average delay in the diagnosis of acute Charcot has been reported to be around 29 weeks.
      Common misdiagnoses include cellulitis, erysipelas, deep vein thrombosis (DVT), venous
      insufficiency, gout, pseudogout, acute inflammatory arthritis, fracture, sprain, tumor,
      septic arthritis, osteomyelitis, Sudeck's atrophy, and rheumatoid arthritis. Delay in prompt
      diagnosis and initiation of treatment results in progression of the pathology resulting in
      rigid osseous deformity of the foot increasing the risk of callus formation, ulceration,
      infection, and lower extremity amputation by 15- to 40-fold .With the propensity for
      misdiagnosis and high potential for progression to a rigid foot deformity, early recognition
      and prompt initiation of treatment is paramount.

      Radiographs are the primary initial imaging method for evaluation of the foot in suspected
      CNO. However, they may initially be normal or show subtle fractures and dislocations.
      Magnetic resonance imaging (MRI) has a higher sensitivity that allows detection of subtle
      changes in the early stages of active CNO when X-rays could still be normal. MRI primarily
      images protons in fat and water and can depict anatomy and pathology in both soft tissue and
      bone in great detail because of its unique capability of differentiating tissues with high
      detail.

      Treatment of CNO is aimed at offloading the foot, treating bone disease, and preventing
      further foot fractures. Because of the various etiologies of increased local bone resorption
      and/or secondary osteoporosis in patients with CNO and limited randomized placebo-controlled
      trials in this area, treatment guidelines are largely based on professional opinion rather
      than the highest level of clinical evidence. Hence, there remains a dearth of evidence based
      medical management for Charcot neuroarthropathy. Offloading at the acute active stage of the
      Charcot foot is the most important management strategy and could arrest the progression to
      deformity. Ideally, the foot should be immobilized in an irremovable total contact cast
      (TCC), which is initially replaced at 3 days, then checked each week. Edema reduction is
      often remarkable in the first few weeks of treatment. The cast should be changed frequently
      to avoid "pistoning" as the edema subsides.

      However, It is important to take into consideration that TCC may actually have unfavorable
      consequences including unnatural stress patterns, increased instability, loss of muscle tone,
      proprioception and boe density.Also, they are not designed to affect the underlying
      physiological mechanisms that cause bone destruction.In this context, treatment by
      antiresorptive drugs emerges as an attractive option. Bone turnover in patients with active
      CNO is excessive, hence bisphosphonates, by inhibiting osteoclast mediated resorption, have
      an important role to play. However, there is little evidence to support their use at
      present.Both oral and intravenous bisphosphonates have been studied in the treatment of CNO
      in small randomized, double-blind, controlled trials or in retrospective controlled studies.
      Whatever the precise pathophysiological mechanism of CNO, bone resorption and osteoclastic
      hyperactivity is a major feature of the early acute stage of this condition and makes the use
      of bone-resorption-inhibiting agents such as bisphosphonates(BPs) a logical therapeutic
      approach. Theoretically, pharmacological treatment of CNO by BPs, which inhibit osteoclastic
      resorption and may have direct anti-inflammatory properties, might slow or even stop the bony
      destruction through its ability to cause macrophage apoptosis.

      Selby et al first reported the use of a BP in the treatment of CNO. They administered 30 mg
      pamidronate i.v.,followed by five infusions of pamidronate 60 mg every 2 weeks for 12 weeks
      in six patients with diabetes and acute CNO. The treatment was associated with improvement in
      local pain and a significant reduction in the activity of the CNO as measured by the decrease
      in the temperature of the affected foot, from 3.4±0.7°C (mean±SE) to 1.0±0.5°C (p 0.05).
      There was also a significant reduction in bone turnover as judged by alkaline phosphatase
      (ALP) level, which fell by 25±3% compared with initial values (p<0.001). Stansberry et al in
      1999 reported a decrease in peak cutaneous blood flow in response to the infusion of 90 mg
      pamidronate i.v. over 24 h in 20 patients with diabetes and CNO, suggesting a
      anti-inflammatory action of pamidronate. In 1999, Young reported anecdotally two cases of
      diabetic acute CNO treated with i.v. infusions of pamidronate associated with immobilisation.
      After 3 months, the clinical outcome was judged favourable with a reduction in clinical signs
      and an absence of deformity. Pakarinen et al. in 2002 retrospectively analysed clinical
      records and X-rays of 36 feet with CNO from 1994 to 2000. Eighteen patients received BPP
      treatment (pamidronate 30-60 mg i.v. once a week for 6 weeks) and no complications were
      registered. There was no statistically significant difference in casting time between
      patients who received (11 weeks) and patients who did not receive (13 weeks) pamidronate. In
      this series, pamidronate infusions were used for selected individuals without any striking
      benefits or disadvantages. Clinically, treatment with BP was associated with a more rapid
      decrease in skin temperature, but this effect was not sustained. Effect on the pain differed
      among studies, with one showing improvement but another showing none.Pakarinen et al tried
      Zoledronic acid and reported that it did not reduce the duration of immobilization. Rather
      there was an increase in total time for casting in subjects treated with Zoledronic
      acid.Similar observations about longer time of immobilization with the use of BPs was
      reported in the the recent multicentric observational audit of acute diabetic CNO in the UK.

      Randomised trials looking into possible use of glucocorticoids in management of active CNO
      have not been undertaken, possibly because of only recent understanding of the role of acute
      inflammation triggering the osteolysis that characterizes CNO. Intravenous
      supra-pharmacological doses of corticosteroids have been used in various inflammatory and
      autoimmune conditions because they are cumulatively less toxic than sustained steroid
      treatment at lower quantitative dosage. Their action is supposed to be mediated through
      non-genomic actions within the cell. When corticosteroids are administered as pulses, an
      immediate profound anti-inflammatory effect is achieved, inflammatory damage is minimized ,
      toxicity is low and there is no prolonged suppressive effect on the hypothalamic-pituitary
      axis. But there are no randomized trials looking into the efficacy and potential benefit of
      methylprednisolone in CNO as of date.

      Hence this trial was designed to compare the therapeutic efficacy and profiles of two well
      known agents Zoledronic acid (antiresorptive) and Methylprednisolone (anti-inflammatory) in
      patients of diabetes mellitus with active CNO of foot.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Triple (Participant, Care Provider, Investigator)
measure: Time for resolution of active Charcot foot
time frame: 6 months
measure: Time for reduction in levels of inflammatory cytokines (>= 50%)
time frame: 6 months
measure: Time for radiologic resolution/reduction on MRI
time frame: 6 months
arm group label: Zoledronic acid
arm group type: Experimental
description: Bisphosphonate Zoledronic acid
arm group label: Methylprednisolone
arm group type: Active Comparator
description: Glucocorticoid Methylprednisolone
arm group label: Placebos
arm group type: Placebo Comparator
description: Placebo normal saline
intervention type: Drug
intervention name: Zoledronic Acid
description: Zoledronic acid 5mg intravenous once a month for 3 months
arm group label: Zoledronic acid
other name: Zoledronate
intervention type: Drug
intervention name: Methylprednisolone
description: Methylprednisolone 1gm intravenous once a month for 3 months
arm group label: Methylprednisolone
other name: MPS
intervention type: Drug
intervention name: Placebos
description: Normal saline intravenous once a month for 3 months
arm group label: Placebos
other name: NS
criteria: 
gender: All
minimum age: 18 Years
maximum age: 70 Years
healthy volunteers: No
last name: Anil Bhansali, DM
role: Study Director
affiliation: Postgraduate Institute of Medical Education and Research
facility: 
country: India
responsible party type: Principal Investigator
investigator affiliation: Postgraduate Institute of Medical Education and Research
investigator full name: Ashu Rastogi
investigator title: Assistant Professor
mesh term: Arthropathy, Neurogenic
mesh term: Diabetes Mellitus
mesh term: Diabetes Complications
mesh term: Zoledronic Acid
mesh term: Methylprednisolone
mesh term: Methylprednisolone Acetate
mesh term: Methylprednisolone Hemisuccinate
mesh term: Prednisolone
mesh term: Prednisolone acetate
mesh term: Prednisolone hemisuccinate
mesh term: Prednisolone phosphate
sharing ipd: No